Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

ommercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the SEC and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2007 filed with the SEC on Form 40-F and our quarterly report for the three months ended September 30, 2008 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: '/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Jose, California (PRWEB) April 23, 2015 ... Predictive diagnostics refer to a series of genetic ... as cystic fibrosis, Lou Gehrig's disease, Huntington's disease, ... in examining the gene composition and interaction in ... the disease as well as the response to ...
(Date:4/23/2015)... Proove Biosciences , a commercial ... to announce the launch of Proove Non-Opioid ... 62 genetic variations to predict good versus poor ... non-opioid pain medications, namely ibuprofen (brand name Advil, ... Xanax) and acetaminophen (brand name Tylenol). , ...
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Delpor, ... today announced that the United States Patent and Trademark ... Company’s NANOPOR™ technology. US Pat. No. ... Delpor’s microfabricated drug delivery device for the ... proprietary NANOPOR™ technology for the sustained (zero-order) release of ...
(Date:4/22/2015)... Today, DuPont announced it has ... microbiome discovery company. This acquisition will build on ... both seed and crop protection to discover and ... , “In 2014, the businesses in DuPont’s Agriculture, ... more than $1 billion in biological solutions across ...
Breaking Biology Technology:Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3DuPont Acquires Taxon Biosciences, Inc. 2DuPont Acquires Taxon Biosciences, Inc. 3DuPont Acquires Taxon Biosciences, Inc. 4
... Draper Laboratory, in conjunction with the National Academy of Engineering (NAE), ... about the impact engineers have had on our daily lives, and ... awarded "Engineering,s Nobel" since 1989. , ... Cambridge, MA ...
... Inc. (Nasdaq: SVNT ) today announced the ... Vice President, Chief Financial Officer & Treasurer. Mr. ... Savient,s Chief Financial Officer, effective immediately. "We are ... Vice President of Corporate Finance and Controller, David will ...
... SAN DIEGO, Feb. 12 Volcano Corporation,(Nasdaq: ... sales of,products for the diagnosis and treatment of coronary ... participating in the Roth Capital Partners,21st Annual Growth Stock ... The presentation by Scott Huennekens, president and chief ...
Cached Biology Technology:New Educational Website Celebrates the Accomplishments of Engineers 2Savient Announces Appointment of David Gionco as Chief Financial Officer 2Savient Announces Appointment of David Gionco as Chief Financial Officer 3Savient Announces Appointment of David Gionco as Chief Financial Officer 4Volcano Corporation Presentation at Roth Capital Partners Conference to Be Webcast 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/24/2015)... 24, 2015   Crossmatch ™, a leading ... that its U.are.U ® 4500 Fingerprint Readers ... Bros . to achieve PCI compliance for Point-of-Sale ... to the POS terminal, protecting the retailer and ... breaches. With one-third of worldwide ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... - A Purdue University study shows dairy has an advantage ... Connie Weaver, distinguished professor and head of the food and ... dry milk were longer, wider, more dense and stronger than ... carbonate is the most common form of calcium used in ...
... biologist Dr. Gary G. Borisy, director and CEO of ... The National Academy of Sciences (NAS), an honorific society ... The achievement, considered one of the highest honors in ... Academy,s 146th annual meeting in Washington, D.C. Dr. Borisy ...
... calve from the northern front of the Wilkins Ice Shelf ... follows the collapse three weeks ago of the ice bridge ... The ice bridge, which effectively formed a barrier pinning ... Shelf, collapsed on 5 April removing about 330 sq km ...
Cached Biology News:Purdue study finds dairy better for bones than calcium carbonate 2MBL director and CEO and cell biology pioneer Gary Borisy elected to National Academy of Sciences 2MBL director and CEO and cell biology pioneer Gary Borisy elected to National Academy of Sciences 3Satellite imagery shows fragile Wilkins Ice Shelf destabilized 2
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... The Eclipse is a state-of-the-art separation ... Fractionation (AFFF) technique. The Eclipse integrates easily ... DAWN, miniDAWN Tristar, as well as the ... size and molar mass distributions of the ...
... for determining the absolute count of CD34+ ... peripheral blood samples, and leukapheresis samples. These ... cell count and a total CD45 (leucocyte) ... use in the BD Procount progenitor cell ...
... Protein A and, until recently, no readily available ... purification. Standard methods for IgM purification generally are ... for removing all of the major impurities present ... Pierce has developed an easy-to-use affinity matrix and ...
Biology Products: